HRP20151443T1 - Terapijsko sredstvo protiv stenoze kralježniäśnog kanala - Google Patents
Terapijsko sredstvo protiv stenoze kralježniäśnog kanala Download PDFInfo
- Publication number
- HRP20151443T1 HRP20151443T1 HRP20151443TT HRP20151443T HRP20151443T1 HR P20151443 T1 HRP20151443 T1 HR P20151443T1 HR P20151443T T HRP20151443T T HR P20151443TT HR P20151443 T HRP20151443 T HR P20151443T HR P20151443 T1 HRP20151443 T1 HR P20151443T1
- Authority
- HR
- Croatia
- Prior art keywords
- spinal canal
- stenosis
- canal stenosis
- therapeutic agent
- intended
- Prior art date
Links
- 208000031481 Pathologic Constriction Diseases 0.000 title claims 10
- 208000037804 stenosis Diseases 0.000 title claims 10
- 230000036262 stenosis Effects 0.000 title claims 10
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- OJQMKCBWYCWFPU-UHFFFAOYSA-N ACT-333679 Chemical compound C=1C=CC=CC=1C1=NC(N(CCCCOCC(O)=O)C(C)C)=CN=C1C1=CC=CC=C1 OJQMKCBWYCWFPU-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- QXWZQTURMXZVHJ-UHFFFAOYSA-N selexipag Chemical compound C=1C=CC=CC=1C1=NC(N(CCCCOCC(=O)NS(C)(=O)=O)C(C)C)=CN=C1C1=CC=CC=C1 QXWZQTURMXZVHJ-UHFFFAOYSA-N 0.000 claims 1
- 210000000115 thoracic cavity Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Claims (3)
1. Sredstvo namijenjeno upotrebi u liječenju stenoze kralježničnog kanala, naznačeno time što sadrži 2-{4-[N-(5,6-difenilpirazin-2-il)-N-izopropilamino]butiloksi}octenu kiselinu ili 2-{4-[N-(5,6-difenilpirazin-2-il)-N-izopropilamino]butiloksi}-N-(metilsulfonil)acetamid, ili njihove farmaceutski prihvatljive soli, kao aktivni sastojak.
2. Sredstvo u skladu s patentnim zahtjevom 1, namijenjeno upotrebi u skladu s patentnim zahtjevom 1, naznačeno time što je stenoza kralježničnog kanala stenoza kanala cervikalne kralježnice, stenoza kanala torakalne kralježnice, stenoza kanala lumbalne kralježnice, difuzna stenoza kralježničnog kanala ili stenoza kanala sakralne kralježnice.
3. Sredstvo u skladu s patentnim zahtjevom 1, namijenjeno upotrebi u skladu s patentnim zahtjevom 1, naznačeno time što je stenoza kralježničnog kanala stenoza kanala lumbalne kralježnice.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008162638 | 2008-06-23 | ||
| PCT/JP2009/061285 WO2009157396A1 (ja) | 2008-06-23 | 2009-06-22 | 脊柱管狭窄症治療剤 |
| EP09770106.4A EP2292231B1 (en) | 2008-06-23 | 2009-06-22 | Therapeutic agent for spinal canal stenosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20151443T1 true HRP20151443T1 (hr) | 2016-01-29 |
Family
ID=41444462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20151443TT HRP20151443T1 (hr) | 2008-06-23 | 2015-12-31 | Terapijsko sredstvo protiv stenoze kralježniäśnog kanala |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8629145B2 (hr) |
| EP (1) | EP2292231B1 (hr) |
| JP (1) | JP5527205B2 (hr) |
| KR (1) | KR101626168B1 (hr) |
| CN (3) | CN105168218A (hr) |
| CA (1) | CA2728089C (hr) |
| CY (1) | CY1117080T1 (hr) |
| DK (1) | DK2292231T3 (hr) |
| ES (1) | ES2557303T3 (hr) |
| HR (1) | HRP20151443T1 (hr) |
| HU (1) | HUE025885T2 (hr) |
| PL (1) | PL2292231T3 (hr) |
| PT (1) | PT2292231E (hr) |
| SI (1) | SI2292231T1 (hr) |
| WO (1) | WO2009157396A1 (hr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009218115B2 (en) * | 2008-02-28 | 2013-05-30 | Nippon Shinyaku Co., Ltd. | Fibrosis inhibitor |
| NO2447254T3 (hr) | 2009-06-26 | 2018-05-05 | ||
| WO2011024874A1 (ja) * | 2009-08-26 | 2011-03-03 | 日本新薬株式会社 | 塩基付加塩 |
| PE20181072A1 (es) | 2015-12-02 | 2018-07-04 | Nippon Shinyaku Co Ltd | Composicion farmaceutica que contiene 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isopropilamino]butiloxi}-n-(metilsulfonil)acetamida |
| CN109563055B (zh) * | 2016-07-29 | 2021-12-24 | 成都苑东生物制药股份有限公司 | 氨基吡嗪类化合物或盐、异构体、其制备方法及用途 |
| JOP20190204A1 (ar) | 2017-03-08 | 2019-09-05 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على سيليكسيباغ |
| CN111263754A (zh) | 2017-09-28 | 2020-06-09 | 日本新药株式会社 | 结晶 |
| US10407396B2 (en) * | 2017-11-16 | 2019-09-10 | Apotex Inc. | Crystalline form of selexipag |
| WO2019098300A1 (ja) | 2017-11-16 | 2019-05-23 | 日本新薬株式会社 | 放出制御製剤 |
| KR20220087443A (ko) | 2019-10-23 | 2022-06-24 | 액테리온 파마슈티칼 리미티드 | 셀렉시파그를 포함하는 약제학적 조성물 |
| US20230113077A1 (en) | 2020-01-31 | 2023-04-13 | Actelion Pharmaceuticals Ltd | Controlled release selexipag composition |
| TW202241425A (zh) | 2021-01-29 | 2022-11-01 | 瑞士商艾克泰聯製藥有限公司 | 用於製造二苯基吡𠯤衍生物之程序 |
| TW202239408A (zh) | 2021-01-29 | 2022-10-16 | 瑞士商艾克泰聯製藥有限公司 | 包含二苯基吡𠯤衍生物的醫藥組成物 |
| EP4316489A1 (en) * | 2021-03-31 | 2024-02-07 | Nippon Shinyaku Co., Ltd. | Therapeutic agent for gait disturbance |
| JP7010404B1 (ja) | 2021-03-31 | 2022-02-10 | 日本新薬株式会社 | 歩行障害治療剤 |
| WO2023131608A1 (en) | 2022-01-04 | 2023-07-13 | Actelion Pharmaceuticals Ltd | Controlled release compositions |
| WO2023214059A1 (en) | 2022-05-06 | 2023-11-09 | Actelion Pharmaceuticals Ltd | Diphenylpyrazine compounds as prodrugs |
| WO2024017964A1 (en) | 2022-07-20 | 2024-01-25 | Actelion Pharmaceuticals Ltd | Injectable pharmaceutical composition comprising a diphenylpyrazine derivative |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI316055B (hr) * | 2001-04-26 | 2009-10-21 | Nippon Shinyaku Co Ltd | |
| CA2476406A1 (en) * | 2002-02-19 | 2003-08-28 | Ono Pharmaceutical Co., Ltd. | Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient |
| HUE029417T2 (en) * | 2002-10-10 | 2017-02-28 | Ono Pharmaceutical Co | Microspheres containing ONO-1301 |
| AU2009218115B2 (en) * | 2008-02-28 | 2013-05-30 | Nippon Shinyaku Co., Ltd. | Fibrosis inhibitor |
-
2009
- 2009-06-22 DK DK09770106.4T patent/DK2292231T3/en active
- 2009-06-22 SI SI200931341T patent/SI2292231T1/sl unknown
- 2009-06-22 WO PCT/JP2009/061285 patent/WO2009157396A1/ja active Application Filing
- 2009-06-22 HU HUE09770106A patent/HUE025885T2/en unknown
- 2009-06-22 KR KR1020107027945A patent/KR101626168B1/ko active IP Right Grant
- 2009-06-22 JP JP2010517991A patent/JP5527205B2/ja active Active
- 2009-06-22 CA CA2728089A patent/CA2728089C/en active Active
- 2009-06-22 PT PT97701064T patent/PT2292231E/pt unknown
- 2009-06-22 US US13/000,758 patent/US8629145B2/en active Active
- 2009-06-22 EP EP09770106.4A patent/EP2292231B1/en active Active
- 2009-06-22 ES ES09770106.4T patent/ES2557303T3/es active Active
- 2009-06-22 CN CN201510331290.2A patent/CN105168218A/zh active Pending
- 2009-06-22 CN CN2009801246839A patent/CN102065863A/zh active Pending
- 2009-06-22 PL PL09770106T patent/PL2292231T3/pl unknown
- 2009-06-22 CN CN201310697705.9A patent/CN103690541A/zh active Pending
-
2015
- 2015-12-29 CY CY20151101199T patent/CY1117080T1/el unknown
- 2015-12-31 HR HRP20151443TT patent/HRP20151443T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2009157396A1 (ja) | 2011-12-15 |
| CA2728089C (en) | 2017-04-11 |
| CN105168218A (zh) | 2015-12-23 |
| CN102065863A (zh) | 2011-05-18 |
| EP2292231B1 (en) | 2015-10-21 |
| ES2557303T3 (es) | 2016-01-25 |
| US8629145B2 (en) | 2014-01-14 |
| PL2292231T3 (pl) | 2016-03-31 |
| EP2292231A4 (en) | 2012-03-28 |
| DK2292231T3 (en) | 2015-12-14 |
| US20110105518A1 (en) | 2011-05-05 |
| KR101626168B1 (ko) | 2016-05-31 |
| WO2009157396A1 (ja) | 2009-12-30 |
| CA2728089A1 (en) | 2009-12-30 |
| CN103690541A (zh) | 2014-04-02 |
| SI2292231T1 (sl) | 2016-03-31 |
| HUE025885T2 (en) | 2016-05-30 |
| JP5527205B2 (ja) | 2014-06-18 |
| EP2292231A1 (en) | 2011-03-09 |
| PT2292231E (pt) | 2015-12-31 |
| CY1117080T1 (el) | 2017-04-05 |
| KR20110033125A (ko) | 2011-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20151443T1 (hr) | Terapijsko sredstvo protiv stenoze kralježniäśnog kanala | |
| HRP20201352T1 (hr) | Inhibitor fibroze | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| ES2611483T3 (es) | Agente terapéutico para enfermedad inflamatoria intestinal | |
| WO2011146808A3 (en) | Topical formulation for a jak inhibitor | |
| WO2008096775A1 (ja) | 疼痛疾患治療剤 | |
| RS54651B1 (en) | JANUS KINAS INHIBITORS for the treatment of dry eye and other eye diseases | |
| BRPI0811436A2 (pt) | Composto, uso de um composto, composição farmacêutica, e, metódos para a terapia da dor em um animal de sangue quente, para a terapia da bexiga super ativa em um animal de sangue quente, e para preparar um composto. | |
| AR057422A1 (es) | Uan composicion farmaceutica de liberacion modificada, proceso de preparacion de dicha composicion y metodo para emplear la misma | |
| UA113157C2 (xx) | Спосіб лікування з використанням селективних інгібіторів bcl-2 | |
| EP3251674A3 (en) | Antiviral azasugar-containing nucleosides | |
| DK2451445T3 (da) | Fremgangsmåde til at tørre bibw2992, dets salte og faste farmaceutiske formuleringer omfattende denne aktive ingrediens | |
| EP3626253A3 (en) | Stable formulations of linaclotide | |
| NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
| GEP20094602B (en) | Use of agomelatine in the manufacture of a medicament intended for the treatment of sleep disorders in the depressed patient | |
| HRP20180061T1 (hr) | Indolkarbonitrili kao selektivni modulatori androgenskih receptora | |
| PE20081751A1 (es) | Composicion farmaceutica que comprende un antagonista muscarinico y antagonista beta-2 adrenorreceptor | |
| IL230487B (en) | 6-(n-(7-chloro-1-hydroxy-3,1-dihydrobenzo[c][1,2]oxaborole-5-yl)methylsulfonamido)-5-cyclopropyl-2-(4-fluorophenyl)-n- Methylbenzofuran-3-carboxamide, their salts and pharmaceutical preparations containing them | |
| CA2736751A1 (en) | Salts of n-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide | |
| MY151230A (en) | Novel method | |
| MX2012013872A (es) | Formas de dosificacion oral de bendamustina. | |
| WO2012024583A3 (en) | Oxysterol compounds | |
| HRP20140499T1 (hr) | Upotreba inhibitora histonske deacetilaze u lijeäśenju filadelfija-negativnih mijeloproliferativnih sindroma | |
| HRP20170551T1 (hr) | Tapentadol za liječenje boli kod reumatoidnog artritisa | |
| HRP20180537T1 (hr) | Uporaba agomelatina za pripravu lijekova za liječenje opsesivno-kompulzivnog poremećaja (ocd) |